NCT00507936CompletedPhase 2
A Global, Multicenter, Randomized, Double-Blind Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain
AbbVie (prior sponsor, Abbott)49 sites in 7 countries280 target enrollmentStarted: August 2007Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 280
- Locations
- 49
- Primary Endpoint
- Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP
Study Overview
Brief Summary
This study will compare the efficacy and the safety of ABT-894 (1mg, 2mg or 4mg capsules) administered BID to placebo in the treatment of DNP. Another treatment arm will be Duloxetine 60mg administered once daily (QD). Approximately 275 subjects will be enrolled into the study at approximately 50 sites in both the United States and Europe. The study will be divided into the following periods: Screening/Washout (21 days) followed by a Baseline Visit, an 8-week Treatment Period and a 1-week Follow-up Visit.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •If female, subject is either postmenopausal for at least two (2) years or surgically sterile or is practicing at least one (1) method of birth control.
- •If female, subject must have negative results for pregnancy tests.
- •The subject must have a diagnosis of diabetes mellitus (Type 1 or Type 2) and a diagnosis of DNP.
- •Subject's DNP must be present for a minimum of six (6) months and should have begun in the feet with relative symmetrical onset.
- •Subject has an HgbA1c <=
- •Subjects who have an HgbA1c > 9 and <= 11 may be included in the study.
- •If male, the subject is surgically sterile (vasectomy), is sexually inactive, or is using a barrier method (condom) of birth control for the duration of the study and for 7 days following the last dose of study drug.
Exclusion Criteria
- •The subject has failed previous treatment with duloxetine for DNP.
- •Subject has a diagnosis of narrow-angle glaucoma.
- •Subject has a history of an allergic reaction or intolerance to duloxetine, acetaminophen, or any other NNR agonist.
- •Subject has a diagnosis of fibromyalgia that requires treatment.
- •Subject has a functioning implanted medical device (spinal cord stimulator, intrathecal pump or peripheral nerve stimulator) for the treatment of neuropathic pain.
- •Subject has a history of seizures (febrile may be ok) or major depressive episode within the past two (2) years or major psychiatric disorder including bipolar disorder, schizophrenia or borderline personality disorder.
- •Subject has a history of myocardial infarction (MI) within six (6) months of the Screening Visit.
- •Subject has unstable angina.
- •Subject has ventricular arrhythmia requiring anti-arrhythmic therapy.
- •Subject has undergone a cardiac revascularization procedure within 30 days of Screening.
- •Subject has uncontrolled hypertension (HTN) defined as a systolic blood pressure (BP) >= 160 and/or a diastolic blood pressure (BP) >= 100 at Screening and/or Baseline.
- •Subject has a clinically significant abnormal ECG at Screening
- •Subject has an active malignancy of any type or has been diagnosed with or treated for cancer within the past 5 years.
- •Subject has a positive result for drugs of abuse at Screening with the exception of a positive result for a known prescribed medication.
- •Subject's screening laboratory results show hepatitis A, B or C.
- •Subject has a known or suspected history of Human Immunodeficiency Virus (HIV).
Arms & Interventions
A
Experimental
ABT-894 1 mg BID
Intervention: ABT-894 (Drug)
B
Experimental
ABT-894 2 mg BID
Intervention: ABT-894 (Drug)
C
Experimental
ABT-894 4 mg BID
Intervention: ABT-894 (Drug)
D
Placebo Comparator
Intervention: placebo (Drug)
E
Active Comparator
Duloxetine 60 mg QD
Intervention: Duloxetine (Drug)
Outcomes
Primary Outcomes
Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP
Time Frame: Change from baseline to final 24-hour average pain score
Secondary Outcomes
- Proportions of treatment responders; subjects who complete treatment period with 30% improvement(From Baseline to final 24-hour average pain score)
- Mean of 24-hour worst pain severity, average of night pain, and average of morning pain measured by the 11-point Likert scale and from subject's daily diary(Weekly through treatment phase)
- Brief Pain Inventory (BPI) (short form) including Pain Severity(At each visit from Baseline to Week 8 visit)
- Clinician Global Impression: Severity (CGI-S) and Patient Global Impression: Change (PGI-C)(At each visit from Baseline to Week 8 visit)
Investigators
Study Sites (49)
Loading locations...
Similar Trials
Completed
Phase 3
A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque PsoriasisPlaque PsoriasisNCT00570986AbbVie (prior sponsor, Abbott)1,465
Completed
Phase 2
A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic TherapyRheumatoid ArthritisNCT01960855AbbVie276
Completed
Phase 2
A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)Attention-Deficit/Hyperactivity DisorderNCT00391729Abbott221
Terminated
Phase 2
Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's DiseaseCrohn's DiseaseNCT00562887Abbott246
Terminated
Phase 2
A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's DiseaseAlzheimer's DiseaseNCT00069849Abbott64